Your browser is no longer supported. Please, upgrade your browser.
Settings
ALXN Alexion Pharmaceuticals, Inc. daily Stock Chart
ALXN [NASD]
Alexion Pharmaceuticals, Inc.
IndexS&P 500 P/E19.56 EPS (ttm)5.49 Insider Own0.20% Shs Outstand226.02M Perf Week3.43%
Market Cap24.27B Forward P/E9.78 EPS next Y10.98 Insider Trans-40.49% Shs Float223.75M Perf Month-0.23%
Income1.24B PEG1.16 EPS next Q2.44 Inst Own97.70% Short Float1.90% Perf Quarter-8.93%
Sales4.50B P/S5.40 EPS this Y-95.70% Inst Trans-0.83% Short Ratio1.83 Perf Half Y-21.08%
Book/sh45.33 P/B2.37 EPS next Y10.61% ROA9.50% Target Price156.26 Perf Year-9.14%
Cash/sh9.25 P/C11.62 EPS next 5Y16.84% ROE14.00% 52W Range92.56 - 141.86 Perf YTD10.31%
Dividend- P/FCF19.08 EPS past 5Y-40.60% ROI0.40% 52W High-24.29% Beta1.70
Dividend %- Quick Ratio3.60 Sales past 5Y21.60% Gross Margin91.70% 52W Low16.03% ATR4.37
Employees2656 Current Ratio4.00 Sales Q/Q15.10% Oper. Margin32.30% RSI (14)46.83 Volatility3.33% 3.99%
OptionableYes Debt/Eq0.26 EPS Q/Q199.20% Profit Margin29.60% Rel Volume0.81 Prev Close108.26
ShortableYes LT Debt/Eq0.25 EarningsOct 23 BMO Payout0.00% Avg Volume2.32M Price107.40
Recom1.90 SMA20-1.18% SMA50-5.96% SMA200-11.75% Volume1,881,571 Change-0.79%
Jul-31-19Resumed JP Morgan Overweight $172
May-23-19Resumed Goldman Neutral $142
May-23-19Resumed Citigroup Buy
May-23-19Initiated Wedbush Outperform
Apr-10-19Resumed Raymond James Outperform $161
Mar-27-19Reiterated RBC Capital Mkts Outperform $165 → $186
Mar-21-19Reiterated Guggenheim Neutral $135
Feb-22-19Initiated Guggenheim Neutral $135
Aug-07-18Downgrade Stifel Buy → Hold $154 → $130
Feb-05-18Upgrade Evercore ISI In-line → Outperform
Jan-18-18Resumed Credit Suisse Outperform $147
Jan-04-18Downgrade Raymond James Strong Buy → Outperform
Dec-18-17Upgrade Robert W. Baird Neutral → Outperform $150
Oct-23-17Resumed Piper Jaffray Overweight $170
Sep-15-17Initiated RBC Capital Mkts Outperform $161
Sep-13-17Reiterated Leerink Partners Outperform $170 → $182
Sep-13-17Reiterated Deutsche Bank Buy $153 → $158
Sep-05-17Upgrade JP Morgan Neutral → Overweight
Aug-17-17Initiated Evercore ISI In-line $137
Jul-28-17Upgrade Oppenheimer Perform → Outperform
Sep-13-19 11:14AM  Zacks.com featured highlights include: Columbia Sportswear, Fossil Group, Alexion and Shoe Carnival Zacks
09:40AM  ALXN or CBM: Which Is the Better Value Stock Right Now? Zacks
Sep-12-19 06:29AM  Rising P/E: An Often-Ignored Trick to Pick 5 Winning Stocks Zacks
Sep-11-19 10:49AM  Biotech Stock Roundup: AMGN's Lung Cancer Candidate, ALXN's Deal With Eidos in Focus Zacks
10:23AM  3 Hot Biotechs with High Upside Potential TipRanks
Sep-10-19 11:39AM  Alexion (ALXN) In-licenses Amyloidosis Candidate In Japan Zacks
Sep-09-19 10:10AM  Amgen's KRAS Inhibitor Shows Response in Larger NSCLC Group Zacks
09:31AM  Has Alexion Pharmaceuticals (ALXN) Outpaced Other Medical Stocks This Year? Zacks
07:30AM  Alexion and BridgeBio Announce Japanese License Agreement for Eidos Transthyretin Amyloidosis (ATTR) Investigational Medicine Business Wire
Sep-06-19 04:48PM  Bad News Keeps Piling Up For Alexion's Soliris But Shares Just Rallied Investor's Business Daily
08:45AM  3 Reasons Growth Investors Will Love Alexion (ALXN) Zacks
Sep-05-19 10:08AM  Here's Why Alexion Pharmaceuticals Dropped 11% in August Motley Fool
08:05AM  5 Price-to-Book Value Picks for September Zacks
Sep-04-19 06:30AM  Alexion to Present at the 17th Annual Morgan Stanley Global Healthcare Conference Business Wire
Aug-31-19 09:35AM  An Intrinsic Calculation For Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) Suggests It's 41% Undervalued Simply Wall St.
Aug-30-19 04:35PM  Why American Outdoor Brands, Innovative Industrial Properties, and Alexion Pharmaceuticals Slumped Today Motley Fool -10.17%
04:33PM  How Amgen Could Take A Hammer To Sales Of Alexion's Biggest Drug Investor's Business Daily
12:50PM  Options Pop on Alexion Stock Amid Patent Questions Schaeffer's Investment Research
11:33AM  Amgen drug patent challenge slices $2B off Alexion's market cap American City Business Journals
Aug-29-19 09:16AM  Regeneron-Sanofi Get Favorable Ruling Against Amgen in Court Zacks
Aug-28-19 01:19PM  Top Analyst Reports for Costco, PayPal & NextEra Zacks
10:34AM  Biotech Stock Roundup: AMGN to Buy CELG's Otezla, ALXN's Soliris Gets EC Nod & More Zacks
08:30AM  Alexion Announces Upcoming Data Presentations at 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis Business Wire
06:30AM  Alexion to Present at the 14th Annual Citi Biotech Conference Business Wire
06:28AM  Alexion Wins EC Nod for Soliris in Nervous System Disorder Zacks
Aug-27-19 08:58AM  Alexion (ALXN) Down 3.2% After Amgen Buys Otezla From Celgene Zacks
08:30AM  European Commission Approves SOLIRIS® (eculizumab) For the Treatment of Adults with Neuromyelitis Optica Spectrum Disorder (NMOSD) Business Wire
Aug-26-19 09:30AM  ALXN vs. CBM: Which Stock Is the Better Value Option? Zacks
08:28AM  Gilead & Galapagos Close Research & Development Agreement Zacks
08:02AM  Alexion Shares Decline in Wake of Amgen's Deal for Otezla TheStreet.com
Aug-25-19 11:31AM  Should Amgen Finally Buy Alexion Pharmaceuticals? Motley Fool
Aug-24-19 07:29AM  3 Reasons Why Amgen Could Actually Acquire Alexion Motley Fool
Aug-23-19 04:10PM  Why Alexion Makes Sense As A Target, But Amgen Doesn't As A Buyer Investor's Business Daily -6.61%
09:31AM  Why Is Alexion (ALXN) Up 4.6% Since Last Earnings Report? Zacks
09:23AM  Biotech Giant Amgen Could Be Nearing A Massive Takeover: Report Investor's Business Daily
09:15AM  Alexion Pharmaceuticals (ALXN) Jumps: Stock Rises 7.5% Zacks
06:00AM  A Pair of Rare Disease Biotech Concerns Worth a Good Look TheStreet.com
Aug-22-19 01:11PM  Alexion Higher on Spanish Report, Cited by Analyst, That Amgen Will Make Bid TheStreet.com +7.53%
12:01PM  MyoKardia Begins Dosing in Phase I Study on Heart Candidate Zacks
Aug-21-19 11:08AM  NuCana Stops Patient Enrollment in Pancreatic Cancer Study Zacks
08:45AM  Alexion (ALXN) is an Incredible Growth Stock: 3 Reasons Why Zacks
Aug-20-19 05:14PM  Inovio Ends Enrollment in Anal Dysplasia Study on VGX-3100 Zacks
04:47PM  Nabriva (NBRV) Gains FDA Approval for Pneumonia Drug Xenleta Zacks
Aug-15-19 09:30AM  Has Alexion Pharmaceuticals (ALXN) Outpaced Other Medical Stocks This Year? Zacks
Aug-14-19 09:35AM  Amgen (AMGN) Soars to 52-Week High, Time to Cash Out? Zacks
08:34AM  Zacks Industry Outlook Highlights: Gilead Sciences, Regeneron Pharmaceuticals, Amgen, Vertex Pharmaceuticals and Alexion Pharmaceuticals Zacks
Aug-13-19 11:24AM  Canadian drug price regulator may be flexible on rare diseases Reuters
10:43AM  Mergers & Acquisitions Take Center Stage in Biotech Industry Zacks
09:40AM  Can Value Investors Consider Alexion (ALXN) a Worthy Pick? Zacks
Aug-11-19 10:15AM  Better Buy: Vertex Pharmaceuticals vs. Alexion Pharmaceuticals Motley Fool
Aug-09-19 09:30AM  ALXN vs. CBM: Which Stock Should Value Investors Buy Now? Zacks
08:24AM  Achillion (ACHN) Reports Wider Y/Y Loss in Q2, Revenues Nil Zacks
Aug-06-19 04:22PM  Biotech ETFs in Focus on Impressive Q2 Earnings Results Zacks
Aug-05-19 08:45AM  Looking for a Growth Stock? 3 Reasons Why Alexion (ALXN) is a Solid Choice Zacks
Aug-03-19 01:15AM  Top Biotech Stocks for February 2019 Investopedia
Aug-02-19 10:43AM  IVERIC bio's (ISEE) Q2 Loss Narrows, Gene Therapy in Focus Zacks
Jul-30-19 01:06PM  Incyte (INCY) Q2 Earnings Beat Estimates, Revenues Up Y/Y Zacks
05:11AM  Alexion Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy? Zacks
Jul-26-19 12:04PM  4 Biotech Stocks Sliding Lower InvestorPlace
08:00AM  Alexion Receives Positive CHMP Opinion for SOLIRIS® (eculizumab) for the Treatment of NMOSD Business Wire
06:31AM  Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN): Will The Growth Last? Simply Wall St.
Jul-25-19 07:48PM  Edited Transcript of ALXN earnings conference call or presentation 24-Jul-19 12:00pm GMT Thomson Reuters StreetEvents
Jul-24-19 04:23PM  Why This Biotech Stock Is Cannibalizing Itself To Analyst's Applause Investor's Business Daily
03:00PM  Alexion Pharmaceuticals Tops Expectations in Q2 Motley Fool
01:54PM  Alexion (ALXN) Q2 Earnings Beat Estimates, Guidance Raised Zacks
12:23PM  Alexion Pharmaceuticals Inc (ALXN) Q2 2019 Earnings Call Transcript Motley Fool
11:52AM  Why This Biotech Stock Is Cannibalizing Itself To Analyst's Applause Investor's Business Daily
07:45AM  Alexion Pharmaceuticals (ALXN) Surpasses Q2 Earnings and Revenue Estimates Zacks
07:08AM  The Daily Biotech Pulse: Jounce Jumps On Licensing Deal, Regulus Hit With Partial Clinical Hold, Genomic Health Added to S&P SmallCap Index Benzinga
06:30AM  Alexion Reports Second Quarter 2019 Results Business Wire
06:00AM  Alexion Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
12:30AM  Is a Beat in the Cards for Celgene's (CELG) Q2 Earnings? Zacks
Jul-23-19 10:56AM  Is a Beat in Store for Repligen (RGEN) This Earnings Season? Zacks
09:29AM  AMAG (AMAG) to Report Q2 Earnings: What's in the Cards? Zacks
07:06AM  Buy 5 High-Flying Stocks Ahead of Q2 Earnings This Week Zacks
Jul-22-19 11:13AM  What's in Store for Anika Therapeutics' (ANIK) Q2 Earnings? Zacks
10:16AM  Alexion (ALXN) to Report Q2 Earnings: What's in the Cards? Zacks
Jul-18-19 10:10AM  Why Alexion (ALXN) is Poised to Beat Earnings Estimates Again Zacks
08:45AM  Is Alexion (ALXN) a Solid Growth Stock? 3 Reasons to Think " Yes " Zacks
Jul-17-19 10:32AM  Alexion Pharmaceuticals (ALXN) Reports Next Week: Wall Street Expects Earnings Growth Zacks
09:30AM  ALXN or ALKS: Which Is the Better Value Stock Right Now? Zacks
09:20AM  New Strong Buy Stocks for July 17th Zacks
09:00AM  Alexion (ALXN) Moves to Strong Buy: Rationale Behind the Upgrade Zacks
08:53AM  6 Low Price-to-Book Value Stocks to Buy for Solid Returns Zacks
Jul-15-19 09:08AM  How Much Are Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) Insiders Taking Off The Table? Simply Wall St.
Jul-14-19 07:30AM  3 Top Biotech Stocks to Buy for the 2nd Half of 2019 Motley Fool
Jul-13-19 07:26AM  Health care is one of the stock markets healthiest sectors right now MarketWatch
Jul-10-19 06:30AM  Alexion to Report Second Quarter 2019 Results On Wednesday, July 24, 2019 Business Wire
Jul-08-19 10:42AM  Health stocks under pressure in wake of Trump plan to issue executive order on drug pricing MarketWatch
Jul-04-19 08:35AM  Alexion's Ultomiris Receives EU Approval for PNH in Adults Zacks
Jul-03-19 01:00PM  ULTOMIRIS® (ravulizumab) Receives Marketing Authorization from European Commission for Adults with Paroxysmal Nocturnal Hemoglobinuria (PNH) Business Wire
Jul-01-19 11:12PM  How to Invest in Biotech Stocks Motley Fool
Jun-30-19 12:15PM  3 Top Biotech Stocks to Add to Your Watchlist Motley Fool
Jun-28-19 08:45AM  Alexion Receives FDA Approval for Label Expansion of Soliris Zacks
Jun-27-19 07:31PM  ADDING MULTIMEDIA Alexion Receives FDA Approval of SOLIRIS® (eculizumab) for the Treatment of Adults with Neuromyelitis Optica Spectrum Disorder (NMOSD) who are Anti-Aquaporin-4 (AQP4) Antibody Positive Business Wire
Jun-26-19 11:29AM  Best Stocks to Buy Before July Schaeffer's Investment Research
08:37AM  Biotech Stock Roundup: Vertex, AMAG Drugs Get FDA Nod, Conatus Study Fails & More Zacks
Jun-25-19 11:09AM  8 Stocks May Jump on Takeovers as Market Nears Peak Investopedia
Jun-21-19 11:05AM  Alexion's sBLA for Ultomiris Gets Priority Review From FDA Zacks
10:01AM  3 Big Biotechs Hold Growth Potential in Second Half of 2019 Zacks
Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis. It also provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia; and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. In addition, the company conducts Phase III clinical trials for ALXN 1210 (IV) that is in Phase III clinical trials for the treatment of PNH and aHUS; ALXN1210 (Subcutaneous), which is in Phase I for PNH and aHUS; and Soliris (eculizumab) for the treatment of myasthenia gravis and neuromyelitis optica spectrum disorder. Further, it develops ALXN1840 (WTX101) that is in Phase III clinical trials for the treatment of Wilson disease; and ALXN1830 (SYNT001), which is in Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other healthcare providers in the United States, Europe, the Asia Pacific, and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc. to use drug-delivery technology in the development of subcutaneous formulations for its portfolio of products; collaboration with Dicerna Pharmaceuticals, Inc. to discover and develop RNAi therapies for complement-mediated diseases, as well as with Zealand Pharma A/S; strategic agreement with Caelum Biosciences, Inc. to advance the development of CAEL-101 for light chain (AL) amyloidosis; and partnership with Affibody AB. The company was founded in 1992 and is headquartered in Boston, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Franchini Indrani LallEVP, Chief Compliance OfficerJul 01Sale132.784,500597,51029,627Jul 02 04:41 PM
SARIN ARADHANAChief Strategy & Business OffJun 21Sale132.0057876,29630,201Jun 24 04:45 PM
BAKER BROS. ADVISORS LPDirectorMay 30Sale120.9757,4496,949,754952,874May 30 05:16 PM
BAKER BROS. ADVISORS LPDirectorMay 29Sale122.20119,06214,548,851959,035May 30 05:16 PM
BAKER BROS. ADVISORS LPDirectorMay 28Sale126.53123,48915,624,859971,803May 30 05:16 PM
Bazarko DanielSVP, Controller, CAOFeb 14Sale126.002,000252,0005,020Feb 19 07:29 PM
HANTSON LUDWIGCEODec 31Sale95.853,244310,937150,696Jan 03 06:07 PM
Franchini Indrani LallEVP, Chief Compliance OfficerNov 28Sale118.132,605307,72929,304Nov 30 06:15 PM